Comprehensive Review

Introduction
Invasive cervical cancer is the second most common cause of cancer-related death worldwide in women. An estimated 500,000 cervical cancer cases were diagnosed in 2006, resulting in > 275,000 deaths. 1 There is an increased burden of disease in less-developed regions of the world such as Africa, Southeast Asia, and Central and South America. In the United States, an estimated 6.2 million new cases of human papillomavirus (HPV) infection will occur annually in 2008, with an estimated 11,070 cases of invasive cervical cancer and approximately 3870 related deaths. 2 Human papillomaviruses are classified into 2 groups: nononcogenic types, which are commonly associated with external genital warts, and oncogenic types, which can cause malignant and premalignant transformation of the lower genital tract causing a proportion of vaginal, vulvar, and penile as well as anal and oropharyngeal cancers. The 2 most common nononcogenic HPVs that cause warts on the anogenital mucosa are HPV 6 and HPV 11. Infection with oncogenic HPV is a necessary and causative precursor event in virtually all cases of cervical cancer. 3 This article discusses the current indications for HPV prophylactic vaccination and explores some possible scenarios that potentially augment vaccine use beyond current approval labeling. The efficacy and safety of the vaccines are presented. Potential barriers to vaccination and future vaccine-related developments are also discussed.
Burden of Disease
Well over 100 HPV types have been fully sequenced, of which > 40 infect the genital mucosa. More importantly, approximately 13-15 of these are known to be oncogenic or high-risk virus types; these are the virus types responsible for virtually all cervical cancers. Human papillomavirus is unique because it is both non-viremic and immuno-evasive in that it uses many mechanisms that prevent recognition by the host immune response, and a natural immune 
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With the approval of a vaccine to prevent human papillomavirus (HPV) infection and the pending approval of a second vaccine, an exciting era has dawned that provides clinicians the opportunity to prevent a majority of lower genital tract cancers. Herein, we describe the quadrivalent and bivalent prophylactic HPV vaccines and examine how they can be incorporated into clinical practice. Effi cacy and safety of the vaccines are discussed as are potential barriers to vaccination. Future questions and challenges are also reviewed. A quadrivalent virus-like particle vaccine has now been approved for use in girls and women ages 9-26 years. A second bivalent vaccine could be available soon. Th e development of these vaccines targeted against 2 oncogenic types of HPV infection (HPV 16 and 18) has made it possible to eliminate approximately 70% of all invasive cervical cancers in women worldwide and decrease the incidence of other lower genital tract cancers and precancers. Vaccine effi cacy in clinical trials has been outstanding, with nearly 100% protection against high-grade lesions because of HPV vaccine types. It is extremely important that vaccinated and unvaccinated women continue with recommended cervical cancer screening because not all oncogenic HPV types are covered in currently developed vaccines. Prevention of most cervical cancer and a notable proportion of cervical precancers and other lower genital tract cancers is now possible with the clinical availability of prophylactic vaccination for girls and young women. Prevention of genital warts is also possible with the quadrivalent vaccine. However, knowledge about HPV infection and cervical cancer as well as the need to vaccinate against oncogenic HPV infection is still lacking among women and physicians; thus, continued education of patients and clinicians is necessary to optimize vaccine use and assure ongoing cytologic screening. response to the virus is generally unreliable. Oncogenic HPV infects basal keratinocytes, resulting in loss of normal cell cycle control via the upregulation of viral gene expression, specifically resulting in E6 and E7 overexpression. HPV 16 accounts for nearly 60% of all cervical cancers and HPV 18 accounts for another 10%-20%. 4 Recent US data estimates that nearly 25 million women between the ages of 14 and 59 years are currently infected with HPV, 3 and > 80% of women will acquire a genital HPV infection by age 50. 5 The quality of life and financial effects of HPV infection are significant. In 2001, the estimated direct costs associated with cervical precancers were 3.6 billion US dollars. 6 Total estimated annual healthcare costs of HPV-related conditions in the US have ranged from 2.3 billion to 4.6 billion US dollars. Obviously, costs are even more significant in developing countries because of the high incidence of cancer. Women's responses to a diagnosis of an HPV infection can result in a number of emotional responses, including depression, anxiety, and anger, and thus quality of life ramifications from HPV infection are notable. 7, 8 
Vaccine Approval
The quadrivalent vaccine (Gardasil®), approved in June 2006 in the United States, is a noninfectious, recombinant vaccine prepared from highly purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV types 6, 11, 16, and 18 (Table 1) . A yeast expression system was used to produce VLPs of these 4 individual HPV types that were then incorporated into the vaccine. The adjuvant agent consists of amorphous aluminum hydroxyphosphate sulfate. The vaccine is approved for intramuscular (IM) administration at 0, 2, and 6 months ( Figure 1 ). Each dose contains 0.5 mL of liquid that is composed of approximately 20 μg of HPV 6 L1 protein, 40 μg of HPV 11 L1 protein, 40 μg of HPV 16 L1 protein, and 20 μg of HPV 18 L1 protein. This was the first prophylactic vaccine to be approved by the US FDA. 9 A second prophylactic HPV vaccine is pending US FDA approval and has been approved in a number of countries globally. This vaccine is a bivalent vaccine (Cervarix®). This prophylactic VLP vaccine is similar in many respects to the quadrivalent vaccine. There are, however, some distinguishing features between them. The bivalent vaccine protects against oncogenic HPV types 16 and 18 but does not cover the nononcogenic HPV types 6 and 11. The bivalent vaccine consists of VLPs composed of L1 capsid proteins produced in a baculovirus system. The vaccine contains a unique adjuvant agent consisting of aluminum and a proprietary lipid agent known as AlSO 4 (aluminum hydroxide and deacylated monophosphoyl lipid A). The adjuvant agent boosts antibody production to higher levels than those seen in natural infection and higher levels than seen with the aluminum salt alone. At present, the clinical implications of higher antibody levels remains unclear because it is unknown whether there is an absolute level of detectable antibody that correlates with protective immunity to infection. Each dose contains 0. Both vaccines share a common important feature regarding production. There is no viral DNA core within either vaccine; thus, there is no expected risk for activation of oncogenes from the vaccine or that the vaccine would transmit HPV to a vaccine recipient. Administration of the vaccine results in type-specific antibody production against each of the individual HPV subtypes. Efficacy data from both vaccines suggest that cross-protection against other HPV types beyond the specific HPV vaccine types might be elicited, although this appears to be limited to a small number of HPV types, and the clinical implications of these data are yet to be confirmed.
Vaccine Efficacy
The efficacy of L1 VLP vaccines is mediated by the production of humoral (antibody) immune responses. Both HPV vaccines have been shown to be highly efficacious against the prevention of high-grade cervical precancers. [9] [10] [11] [12] [13] [14] In a study of > 12,000 women randomized to receive the quadrivalent HPV vaccine or placebo, the vaccine was 98% effective in the prevention of HPV 16-and 18-related cervical intraepithelial neoplasia (CIN) 2 and 3 and adenocarcinoma in situ in women who were naive to HPV vaccine types at enrollment. 12 In an analysis including women with prevalent HPV infection or CIN at enrollment, the quadrivalent vaccine efficacy against HPV 16-and 18-related CIN 2 and 3 was 44%. Additionally, the quadrivalent vaccine has shown a high degree of efficacy for the prevention of genital warts as well as vulvar and vagi- 
Vaccine Safety
Overall, the bivalent and quadrivalent vaccines have been well tolerated. [9] [10] [11] [12] [13] [14] The most common reported side effects are injectionsite reactions and localized pain at the site of injection. Eighty-four percent of women who received the quadrivalent vaccine reported injection-site adverse events compared with 78% of women in the placebo group. 12 Serious systemic events have been rare for both vaccine types. The quadrivalent vaccine is currently listed as an FDA Category B drug in the case of pregnancy. The proportion of women with live births, delivery difficulties, spontaneous abortions, and late fetal demises was similar between vaccine and placebo groups. An external analysis of congenital anomalies in fetuses from mothers who received the quadrivalent vaccine found that the pattern of anomalies seen was consistent with that of the general population. The proportion of women with new onset chronic diseases, autoimmune disease, or other conditions has not been shown to be higher after vaccination. 14 Following population-based implementation of the vaccine in many countries worldwide, large vaccine effectiveness studies are currently ongoing to investigate changes in these and other more rare clinical outcomes over time because longterm effects are unknown.
Current Indications
The ideal cohort for vaccination consists of preadolescent females prior to initial HPV exposure, ie, those who have not been sexually active. Thus, the US Advisory Committee on Immunization Practices recommended HPV vaccination for females aged 11-12 years as the target group. The committee also recommended "catch-up" vaccination of women aged 13-26 years who have not been previously vaccinated or who have missed a vaccination because women within this age group are at a notably higher risk of HPV infection. Although public health priorities target providing vaccination to younger women not yet exposed, widened vaccination can also potentially benefit women aged > 26 years who have not been previously exposed to HPV 6, 11, 16, or 18 . Figure 2 shows the proposed administration schematic by age. Figure 1 shows the administration schedules for the quadrivalent and bivalent vaccines.
Barriers to Vaccination
The development of vaccines targeted against 2 oncogenic HPV types has made it possible to eliminate approximately 70% of all invasive cervical cancers in women, yet vaccine uptake in the nearly 2 years of approval has not been close to universal even in resourcerich countries such as the United States. Important barriers include lack of education, vaccine stigmatization, and cost. Knowledge about HPV infection, its prevalence, mode of transmission, and its relation to the development of cervical cancer as well as the need to vaccinate against oncogenic HPV infection is still lacking among women and physicians. 15 A patient's belief in their ability and intention to receive the vaccine is associated with a higher level of knowledge of HPV infection, perceived health and safety-related benefits for self and partner protection, normative beliefs, a perceived higher HPV disease severity, previous pregnancy, and a history of previous sexually transmitted infections. Lack of insurance and higher perceived barriers to vaccination have been associated with lower intentions to vaccinate. 16 Therefore, continued tailored and targeted educational and awareness initiatives are required for healthcare professionals and patients alike. Cost continues to be a barrier for some individuals, although as a society, it appears that there is a cost savings for vaccination. 17 
Future Directions
A number of novel strategies are currently under development that use vaccine strategies that have the potential to alter the future of vaccines against cervical cancer. New prophylactic vaccine strategies are being developed to produce HPV VLP vaccines within different delivery systems (eg, nasal, edible plants), while others are working on developing second-generation vaccines against additional viral types by increasing the number of HPV types used to derive VLP-based vaccines or by using the minor capsid antigen L2. Initiatives to develop therapeutic vaccines are also well under way, including the development of vaccines against early HPV proteins that comprise targets for cellular immunity. Challenges remain and additional data is pending for the utility of male vaccination, duration of protection, value of cross protection, and indications for vaccinating patients aged > 26 years. Despite these challenges, an exciting new era in cancer prevention has dawned.
HPV Vaccination Indications
The upper limit of age is 26 years for approval in the United States, but other countries and emerging data might advocate for vaccination after this age. 
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